Data › Companies › SGRY

Surgery Partners, Inc. (SGRY)

Nasdaq · Services-General Medical & Surgical Hospitals, Nec · Services · CIK 1638833 · fiscal year ends in Dec

Closing price $23.24 on 28 Oct 2026; 52-week range $11.49 to $23.36.

Key figures

The last twelve months reported, with the latest price and balance sheet.

Revenue, last twelve months
$3.4B
Revenue growth
4.0%
Net income, last twelve months
-$88.6M
Earnings per share
-$0.70
Operating margin
11.4%
Net margin
-2.6%
Free cash flow
$187.6M
Return on equity
-5.3%
Market value
$3.0B
Cash
$216.7M
Debt
$3.8B
Debt to equity
2.25
Shares outstanding
130.9M

Financial statements

Revenue, profit and cash flow by fiscal year, each year linked to its annual report.

Fiscal yearYear endRevenueOperating incomeNet incomeEPSFree cash flowFiling
FY202531 Dec 2025$3.3B$389.5M-$77.9M-$0.61$195.6M10-K filed 2 Mar 2026
FY202431 Dec 2024$3.1B$348.8M-$168.1M-$1.33$209.7M10-K filed 7 Mar 2025
FY202331 Dec 2023$2.7B$328.0M-$11.9M-$0.09$205.0M10-K filed 26 Feb 2024
FY202231 Dec 2022$2.5B$345.2M-$54.6M-$0.59$78.2M10-K filed 1 Mar 2023
FY202131 Dec 2021$2.2B$302.2M-$70.9M-$1.12$29.5M10-K filed 1 Mar 2022

By quarter

QuarterQuarter endRevenueNet incomeEPS
Q2 FY202630 Jun 2026$848.9M-$15.0M-$0.12
Q1 FY202631 Mar 2026$810.9M-$35.9M-$0.28
Q4 FY202531 Dec 2025$885.0M-$15.0M-$0.12
Q3 FY202530 Sep 2025$821.5M-$22.7M-$0.18
Q2 FY202530 Jun 2025$826.2M-$2.5M-$0.02
Q1 FY202531 Mar 2025$776.0M-$37.7M-$0.30
Q4 FY202431 Dec 2024$864.4M-$108.5M-$0.86
Q3 FY202430 Sep 2024$770.4M-$31.7M-$0.25

What the company said with its results

From the second quarter of 2026 results, filed 10 August 2026.

  • Revenue rose 2.7% in quarter. Revenues were $848.9 million, compared with $826.2 million in the second quarter of 2025.
  • Same-facility revenue rose 5.0%. Same-facility revenue grew 5.0%, up from 4.4% in the first quarter. Revenue per case rose 4.8% and same-facility cases rose 0.3%.
  • Net loss attributable widened. Net loss attributable to Surgery Partners, Inc. was $15.0 million, compared with a $2.5 million loss in the second quarter of 2025.
  • First-half revenue up 3.6%. Year-to-date revenue was $1,659.8 million, up 3.6%. Year-to-date same-facility revenue rose 4.9%.
  • Revenue per case rose. Revenue per case was $5,057, up from $4,780. Total cases were 167,866, against 172,858 a year earlier.
  • Same-facility cases nearly flat. Same-facility cases rose 0.3% in the quarter and 0.8% year to date, on a days-adjusted basis.
  • Work days unchanged year over year. Both second-quarter periods had 64 work days, so reported and days-adjusted same-facility growth are the same.
  • Facility count rose year over year. Surgical facilities totaled 178 at June 30, against 162 a year earlier and 180 at March 31. Consolidated facilities were 120, up from 115.
  • Salaries and supplies increased. Salaries and benefits were $253.1 million, against $235.2 million. Supplies were $226.8 million, against $215.0 million.
  • Cost of revenues up 4.5%. Total cost of revenues was $658.7 million, against $630.6 million. General and administrative expenses were $36.3 million, against $36.1 million.
  • Transaction costs near prior level. Transaction and integration costs were $18.4 million, against $18.1 million. Of that, M&A costs were $12.5 million and other costs $5.9 million.
  • Litigation costs rose. Other litigation costs were $2.7 million in the quarter, against $0.4 million in the second quarter of 2025.
  • Adjusted EBITDA fell year over year. Adjusted EBITDA was $125.2 million, against $129.0 million. Margin was 14.7%, against 15.6%; year-to-date margin was 13.7%, against 14.5%.
  • Operating income declined. Operating income was $102.1 million, against $111.7 million. Income before income taxes was $32.3 million, against $43.8 million.

Company events

The newest 8-K filings of 143 held.

FiledFormEventItems
26 Oct 20268-KMaterial agreement, Investor update1.01, 7.01, 9.01
17 Sep 20268-KDeal completed2.01, 9.01
10 Aug 20268-KResults2.02, 9.01
24 Jul 20268-KMaterial agreement, Investor update1.01, 7.01, 9.01
5 Jun 20268-KShareholder vote5.07
5 May 20268-KResults2.02, 9.01
2 Mar 20268-KResults, Investor update2.02, 7.01, 9.01
16 Dec 20258-KMaterial agreement, New debt1.01, 2.03, 9.01
12 Dec 20258-KOther events8.01, 9.01
11 Dec 20258-KInvestor update7.01, 9.01
12 Nov 20258-KLeadership change5.02, 9.01
10 Nov 20258-KResults2.02, 9.01

Every filing

The newest filings with the SEC of 261 held.

FiledFormPeriod
28 Oct 2026DEFA14A–
27 Oct 2026DEFA14A–
26 Oct 2026DEFA14A–
26 Oct 2026DEFA14A–
26 Oct 20268-K23 Oct 2026
17 Sep 20268-K14 Sep 2026
10 Aug 202610-Q30 Jun 2026
10 Aug 20268-K10 Aug 2026
24 Jul 20268-K21 Jul 2026
5 Jun 20268-K5 Jun 2026
5 May 202610-Q31 Mar 2026
5 May 20268-K5 May 2026

Insider trades

Form 4 trades by officers, directors and 10% owners, last 12 months.

TradedInsiderTypeSharesPriceValueHeld afterForm 4
18 Aug 2026Deluca Teresa, DirectorPurchase10,000$14.35$143.5K66,84319 Aug 2026
16 Mar 2026Doherty David T, Chief Financial OfficerSale outside a trading plan8,867$12.50$110.8K221,67916 Mar 2026
16 Mar 2026Evans Jason Eric, Chief Executive OfficerSale outside a trading plan20,400$12.47$254.4K920,38616 Mar 2026
13 Mar 2026Burkhalter Danielle, Chief Human Resources OfficerSale outside a trading plan3,469$12.83$44.5K76,86416 Mar 2026
13 Mar 2026Brittenham Marissa, Chief Strategy OfficerSale outside a trading plan3,657$12.54$45.9K94,19616 Mar 2026
12 Mar 2026Baldock Jennifer, Chief Admin & Dev OfficerSale outside a trading plan5,798$13.17$76.4K326,47416 Mar 2026
6 Mar 2026Evans Jason Eric, Chief Executive OfficerSale outside a trading plan11,462$13.79$158.1K662,6809 Mar 2026
6 Mar 2026Doherty David T, Chief Financial OfficerSale outside a trading plan14,574$13.84$201.7K88,8039 Mar 2026
6 Mar 2026Baldock Jennifer, Chief Admin & Dev OfficerSale outside a trading plan10,082$13.70$138.1K332,2729 Mar 2026
6 Mar 2026Burkhalter Danielle, Chief Human Resources OfficerSale outside a trading plan7,736$13.60$105.2K37,1039 Mar 2026
6 Mar 2026Webb William Trenton, American Group PresidentSale outside a trading plan272$13.93$3.8K74,2499 Mar 2026
6 Mar 2026Brittenham Marissa, Chief Strategy OfficerSale outside a trading plan8,785$13.70$120.4K54,6239 Mar 2026

Planned insider sales

Form 144 notices, filed when the sell order goes to the broker.

FiledSellerSharesValuePlanned sale
16 Mar 2026David Doherty, Officer8,867$110.8K16 Mar 2026
16 Mar 2026Jason Eric Evans, Director, Officer20,400$254.4K16 Mar 2026
13 Mar 2026Danielle Burkhalter, Officer3,469$44.5K13 Mar 2026
13 Mar 2026Marissa Brittenham, Officer3,657$45.9K13 Mar 2026
12 Mar 2026William T. Webb, Officer2,045$26.7K12 Mar 2026
12 Mar 2026Jennifer Baldock, Officer5,798$76.4K12 Mar 2026
6 Mar 2026William T. Webb, Officer272$3.8K6 Mar 2026
6 Mar 2026Danielle Burkhalter, Officer7,736$105.2K6 Mar 2026
6 Mar 2026Marissa Brittenham, Officer8,785$120.4K6 Mar 2026
6 Mar 2026Jennifer Baldock, Officer10,082$138.1K6 Mar 2026

Large holders

Schedule 13D and 13G filings by holders of more than 5% of the voting shares.

FiledHolderScheduleStakeShares
26 Oct 2026BCPE Seminole Holdings LP13D amended22.96%30.1M
13 Oct 2026GLENVIEW CAPITAL MANAGEMENT, LLC13G5.4%7.0M
14 Aug 2026King Street Capital Management, L.P.13G4.6%6.1M
15 May 2026Pentwater Capital Management LP13G amended9.7%12.7M
6 May 2026FMR LLC13G amended1.7%2.2M
27 Mar 2026The Vanguard Group13G amended0%0
17 Feb 2026Pentwater Capital Management LP13G amended7.7%10.0M
5 Feb 2026FMR LLC13G amended5.1%6.5M
14 Nov 2025JANUS HENDERSON GROUP PLC13G amended10.2%13.0M
14 Nov 2025Pentwater Capital Management LP13G amended9.1%11.7M

Short interest

Shares sold short and not yet bought back, on each FINRA settlement date.

SettlementShares shortChangeDays to cover
15 Oct 202614.3M-0.13%10.34
30 Sep 202614.3M+7.98%5.35
15 Sep 202613.3M+2.58%6.37
31 Aug 202613.0M+2.39%4.68
14 Aug 202612.7M-6.53%6.03
31 Jul 202613.5M-8.56%8.88
15 Jul 202614.8M-2.13%11.41
30 Jun 202615.1M+5.96%10.42

Funds that hold it

From each fund's latest Form 13F.

214 funds held it at 30 Jun 2026: 101 added and 51 trimmed in the quarter. The largest:

FundSharesValueChange in the quarter
Bain Capital Investors LLC49,946,972$839.1M0
Jupiter Topco LLC13,882,155$233.2M–
Pentwater Capital Management LP11,630,000$195.4M-1,025,000
UBS Group AG8,573,413$144.0M-1,618,368
BlackRock, Inc.6,241,503$104.9M+580,715
King Street Capital Management, L.P.6,058,141$101.8M-4,171,589
T. Rowe Price Investment Management, Inc.5,916,197$99.4M+3,966,477
Dimensional Fund Advisors LP4,943,713$83.1M-352,698
Clearbridge Investments, LLC3,823,179$64.2M-294,877
Vanguard Portfolio Management LLC3,737,712$62.8M+109,281

Peers

Companies in the same industry.

  • HCA Healthcare, Inc. (HCA): revenue $78.0B, market value $101.0B
  • Tenet Healthcare Corp. (THC): revenue $21.8B, market value $21.6B
  • Universal Health Services Inc. (UHS): revenue $18.1B, market value $10.3B
  • Ardent Health, Inc. (ARDT): revenue $6.4B, market value $1.7B

What the company does

Surgery Partners is a Delaware corporation that, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services in the United States. It has more than 200 locations in 30 states, including ambulatory surgery centers ("ASCs"), short-stay surgical hospitals and multi-specialty physician practices. As of 31 December 2025 it owned or operated 176 surgical facilities, made up of 157 ASCs and 19 licensed surgical hospitals. The company describes itself as one of the largest and fastest growing surgical services businesses in the United States. It had approximately 16,000 employees.

How the business is organised

The company reports one segment, Surgical Facilities. It covers ASCs, surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Facilities are owned and run through partnerships or limited liability companies with physicians, physician groups and health care systems. Of the 176 facilities, the company holds majority ownership in 90 and consolidated 121 for financial reporting. For most facilities it provides day-to-day management under a management agreement and receives a fee that is typically a percentage of the facility's revenue. It also makes intercompany loans to some facilities, often secured by a pledge of the facility's assets. In some markets a health care system is an owner alongside the physician investors.

What the facilities do

The facilities mainly perform non-emergency, scheduled surgery. A typical ASC is free-standing and handles outpatient procedures for patients who are not expected to need an overnight stay. Each usually has one to seven operating or procedure rooms. The surgical hospitals focus on less complex elective surgeries with shorter recovery times and are generally not equipped for critical or traumatic injuries.

The company mainly runs multi-specialty facilities and keeps some as single-specialty where that suits the market. By share of cases at consolidated facilities, the mix is:

- Orthopedics and pain management: 40.7% - Gastrointestinal: 24.4% - Ophthalmology: 21.7% - General surgery: 1.9% - Other: 11.3%

How it earns its money

Revenue from consolidated facilities comes from facility fees. These usually cover use of an operating room and recovery room, equipment, supplies, nursing staff and medications. They do not usually include the professional fees of the surgeon or anesthesiologist, which those physicians bill directly. The other 2.5% is other service revenues, mainly management fees from facilities the company does not consolidate.

By payor, patient service revenues at consolidated facilities come from private insurance at 52.3%, government programs at 42.8%, self-pay at 2.7% and other payors at 2.2%. Medicare pays ASCs based on the Outpatient Prospective Payment System, at a percentage of what hospital outpatient departments receive. Hospitals are paid under separate Medicare systems. Most private insurance is paid under written contracts that generally require discounts from the company's established charges.

Who it competes with and how it grows

In each market the company competes with hospitals and other surgical facility operators for physicians and patients. It names HCA Healthcare, Inc., AMSURG Corp., Tenet Healthcare Corporation and Optum, Inc. among the large national companies that own or manage surgical facilities. Physicians choosing to operate in office-based settings are another source of competition.

The company grows by acquiring existing facilities, developing new ones with local physician partners, and recruiting physicians to its facilities. It uses a dedicated acquisition team. It is either a majority owner alongside physicians or a minority owner with possible buy-up options. For new facilities it offers in-house capabilities for structuring partnerships and financing, and it works with architects and construction firms. Marketing is aimed at physicians and at private insurance payors, which the corporate managed care team approaches for contracts.

Rules it works under

The company says it depends on government and private insurance sources of payment. Continued Medicare participation depends on compliance with regulations from the Department of Health and Human Services. It operates in 21 states that have certificate of need laws, which can require approval to build, acquire or expand facilities. Facilities must meet state licensing requirements, and the majority were accredited by either The Joint Commission or the Accreditation Association for Ambulatory Health Care. The filing also describes the federal Anti-Kickback Statute, the Stark Law, HIPAA privacy and security rules and the Emergency Medical Treatment and Active Labor Act as applying to its arrangements with physicians and its hospitals. It runs a company-wide compliance program with training for employees involved in patient care, coding and billing.

Its people

None of the roughly 16,000 employees is covered by a collective bargaining agreement. Most physicians who use the facilities are not employees and are not contractually required to use them. The company generally has contracts with physicians only through partnership and operating agreements, anesthesiology service agreements and medical director agreements. It competes with hospitals and other facilities for physicians, nurses and medical staff, and it notes that nurse and medical support availability is an operating issue in several markets.

*From Surgery Partners's annual report on Form 10-K for the year ended 31 December 2025. [The filing](https://www.sec.gov/Archives/edgar/data/1638833/000163883326000008/sgry-20251231.htm)*

From the company's 10-K.

Services · Nasdaq companies · Every company we cover